Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
J Med Virol. 2021 May;93(5):2971-2978. doi: 10.1002/jmv.26828. Epub 2021 Feb 9.
The aim of this study was to describe the clinical characteristics and outcomes of coronavirus disease 2019 (COVID-19) among people living with HIV (PLWH) in Belgium. We performed a retrospective multicenter cohort analysis of PLWH with either laboratory-confirmed, radiologically diagnosed, or clinically suspected COVID-19 between February 15, 2020 and May 31, 2020. The primary endpoint was outcome of COVID-19. Secondary endpoints included rate of hospitalization and length of hospital stay and rate of Intensive Care Unit (ICU) admission and mechanical ventilation. One hundred and one patients were included in this study. Patients were categorized as having either laboratory-confirmed (n = 65), radiologically-diagnosed (n = 3), or clinically suspected COVID-19 (n = 33). The median age was 51.3 years (interquartile range [IQR] 41.3-57.3) and 44% were female. Ninety-four percent of patients were virologically suppressed and 67% had a CD4 cell count more than or equal to 500 cells/µl. Overall, 46% of patients required hospitalization and the median length of hospital stay was 6 days (IQR 3-15). Age more than or equal to 50 years, Black Sub-Saharan African patients, and being on an integrase strand transfer inhibitor-based regimen were associated with being hospitalized. ICU admission and mechanical ventilation was required for 15% and 10% of all patients respectively. Overall, 9% of patients died while 78 (77%) patients made a full recovery. HIV patients with COVID-19 experienced a high degree of hospitalization despite having elevated CD4 cell counts and a high rate of virologic suppression. Matched case-control studies are warranted to measure the impact that HIV may have on patients with COVID-19.
本研究旨在描述比利时艾滋病毒感染者（PLWH）中 2019 年冠状病毒病（COVID-19）的临床特征和结局。我们对 2020 年 2 月 15 日至 2020 年 5 月 31 日期间实验室确诊、影像学诊断或临床疑似 COVID-19 的 PLWH 进行了回顾性多中心队列分析。主要终点是 COVID-19 的结局。次要终点包括住院率和住院时间、重症监护病房（ICU）入院率和机械通气率。本研究共纳入 101 例患者。患者分为实验室确诊（n=65）、影像学诊断（n=3）或临床疑似 COVID-19（n=33）。中位年龄为 51.3 岁（四分位距 [IQR] 41.3-57.3），44%为女性。94%的患者病毒学抑制良好，67%的 CD4 细胞计数大于或等于 500 个/µl。总体而言，46%的患者需要住院治疗，中位住院时间为 6 天（IQR 3-15）。年龄大于或等于 50 岁、撒哈拉以南非洲裔黑人患者和使用整合酶抑制剂为基础的治疗方案与住院相关。所有患者中有 15%和 10%分别需要 ICU 入院和机械通气。总体而言，9%的患者死亡，78%（77%）的患者完全康复。尽管 CD4 细胞计数升高且病毒学抑制率高，但 HIV 患者 COVID-19 仍需高度住院治疗。需要进行匹配病例对照研究来衡量 HIV 对 COVID-19 患者的影响。
